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(r=-0.235, p=0.039), meaning greater BV variability was associated 
with reduced LENT-SOMA bladder scores. 
Conclusions: We believe that we are the first to document an 
association between interfraction variation of bladder volume and 
long-term bladder toxicity outcomes in image-guided ICB for cervical 
cancer.This is consistent with previous data showing that BV variation 
can avoid overlap of high dose regions within the bladder. Such data 
could justify changing current practice in many centers that do not 
routinely use variable bladder filling protocols. Nonetheless, study is 
ongoing to determine the exact effect of BV changes on distribution of 
high dose areas to further validate this recommendation.  
   
OC-0360  
 
N. Nesvacil1, K. Tanderup2, J. Kallehauge2, J. Lindegaard2 3, 
C. Kirisits3 
1
2Aarhus University Hospital, Department of Oncology, Aarhus, 
Denmark  
3
 
 
Purpose/Objective: Recent analysis of dosimetric variations 
occurring, e.g. due to anatomical variations, within and between 
different BT fractions, have revealed that expected intra- and inter-
fraction uncertainties are of the order of 10% for D90 of HR CTV and 
20-30% for D  for organs at risk, for the physical dose of each BT 
fraction (Nesvacil et al. 2012, Radiother Oncol 103, S2, S33). This 
leads to uncertainties in the total treatment dose by up to 4-7 Gy 
dose-response curves. The aim of this simulation study was to 
estimate this impact for target and OAR.  
Materials and Methods: In this numerical experiment, a dose-dose 
response curve was assumed for D90 of HR CTV and D  for OAR, by a 
logit function, corresponding to typical dose-response curves assessed 
from clinical data (e.g. Tanderup et al. (submitted) and Georg et al. 
(2009, Radiother Oncol 91, 173)). 
Dose response uncertainties were simulated by applying typical dose 
variations for HDR cervix BT in the calculations, and compared to the 
initial dose-response curve. 
A custom IDL script was used to simulate realistic total treatment 
dose values for a range of dose levels, taking into account reported 
standard deviations of intra-/inter-fraction variations, i.e., 10% for D90 
HR CTV ( / =10Gy) and 20% for D  of OAR ( / =3Gy), for a 
schedule with 45Gy EBRT and 4 BT fractions.  
For each dose level 10000 patients were simulated by picking 
uncertainties randomly for each BT fraction according to a N(Di, 2) 
distribution, where Di was the physical fractional dose and  the SD 
typical for variations. Simulated fractional doses were transformed 
For each simulated patient, response probabilities were calculated 
based on the assumed 'dose-response' curves for D90 and D . 
Parameters for the initial curves are given in Fig. 1. 
For each expected dose level, the corresponding calculated response 
probability values based on the simulated doses were plotted. Median 
and mean response probabilities of the simulated doses were 
graphically compared with expected response values at each dose 
level.  
 
 
Results: 
Results: In comparison to the expected dose-response curve, the 
simulations indicate a steeper slope in the low dose region and a 
flattening of the curve in the high-dose region. (Fig. 1) The effect is 
more visible in the case of OAR. 
Conclusions: Our preliminary simulations indicate that the predictive 
power of dose-effect relationships may be significantly influenced by 
dosimetric uncertainties. The steepness of the real dose-effect curve 
may be over- or underestimated depending on the investigated dose-
region. Taking into account random uncertainties, and minimizing 
them might lead to a relaxation of commonly used dose constraints 
for OAR, allowing for better coverage of target structures.  
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Purpose/Objective: Traditionally, vaginal dose points have been 
defined at the vaginal source level, thus not providing dose 
information for the entire vagina. Since reliable vaginal 
dosevolume/surface histograms are hardly available, a strategy for 
comprehensive vaginal dose reporting for combined external beam 
radiotherapy (EBRT) and brachytherapy (BT) was established. 
Materials and Methods: An anatomical vaginal reference point was 
defined at the level of the Posterior-Inferior Border of Symphysis 
(PIBS), plus two points at a distance of ±2cm (mid/introitus 
vagina)(Figure 1).For BT points were selected at 12/3/6/9 o'clock for 
the upper vagina, at the applicator ring surface and 5 mm depth 
(Figure 1). A vaginal reference length (VRL) was defined from ring 
centre to PIBS. Fifty-nine patients treated for cervical cancer were 
included into this retrospective feasibility study.  
 
 
Results: The method was applicable for all patients. The mean total 
51.4 Gy (36.6-91.7) and 5.7 Gy (1.7-49.1). At 5 mm depth from the 
ring, doses were respectively 115.4 Gy (53.2-210.7)/103.2 Gy (29.9-
Conclusions: With this novel system, a comprehensive reporting of 
vaginal doses is feasible. The present study has demonstrated large 
dose variations between patients observed in all parts of the vagina. 
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